MASH Webinar Series 2020
June 15th - 20th
REGISTRATION IS CLOSED!
THANK YOU!
Please preview the webinars below and available packages
Registration automatically includes the chance to win a $50 Amazon giftcard!*
*must be present at the conclusion of the webinar to win
THANK YOU!
Please preview the webinars below and available packages
Registration automatically includes the chance to win a $50 Amazon giftcard!*
*must be present at the conclusion of the webinar to win
MONDAY, JUNE 15TH - 9am - 10am EST
|
Allie Cummings
"Checkpoint Inhibitors and Biomarkers Testing Landscape" |
Immuno-Oncology (I-O) is very promising in personalized cancer treatment. Among I-O drugs, checkpoint inhibitors (anti PD1/PD-L1 and anti CTLA-4) play a dominant role and around 2000 clinical trials are evaluating their efficacy in different indications(1). As the treatment scenario evolves, choosing the appropriate biomarker to select the right patients becomes vital. PD-L1 is a transmembrane protein expressed by tumor cells to escape the immune response. As a biomarker, PD-L1 expression is predictive of a patient’s response to anti PD1/PD-L1 drugs. To date, the FDA has approved six checkpoint inhibitors and four PD-L1 assays, with their specific scoring system. In this talk we will review the checkpoint inhibitors available in the market, we will compare the different PD-L1 scoring systems (TPS, CPS, IC, TC) and point out the role of clinical validation for predictive biomarkers, like PD-L1. Finally we will look at the emerging biomarker and therapeutic cancer strategies.
|
TUESDAY, JUNE 16TH - 1pm - 2pm EST
|
Dr. Julie Tse
"Histology and Comprehensive Genomic Profiling of Tumors for Cancer Patients" |
This presentation will discuss the role of histology in next-generation sequencing (NGS) for cancer patients. Examples of patient cases will be reviewed and basic pathological appearances of different cancer types will be explained. In addition, tips for successful histology for NGS samples will be discussed, as well as strategies for optimizing an NGS workflow. The importance of precision cancer medicine will be highlighted and contrasted to previous blanket methods and approaches.
|
WEDNESDAY, JUNE 17TH - 5pm - 6pm EST
|
Dr. Richard Cartun
"Predictive IHC Marker Testing in Breast Cancer 2020: What Have We Learned?" |
This workshop will review the current state of immunohistochemical testing for estrogen receptor protein, progesterone receptor protein, and HER2 protein overexpression in breast cancer. Invasive, metastatic, and in situ cancer will be covered. The importance of pre-analytics and technical issues in IHC testing will be addressed. Proficiency testing and results from Oncotype DX™ testing will be used to discuss standardization and test validation.
|
THURSDAY, JUNE 18TH - 10am - 11am EST
|
Mark Burton
"DNA-based Next Generation Multiplex Fluorescence Immunohistochemistry" |
There is an increasing demand to identify complex cell phenotypes and understand spatial cellular relationships in tissue. Conventional immunohistochemistry methods are limited in the number of markers that can be detected and consequently the data that can be obtained from an individual sample. This problem is compounded by the need to preserve precious tissue.
In this presentation we will discuss a unique multiplex fluorescence technology for tissue biomarker identification and analysis that can provide in depth investigation of co-localized markers. This method enables simultaneous multi-marker detection in a single sample utilizing existing automated staining and imaging instrumentation. |
FRIDAY, JUNE 19TH - 12pm - 1pm EST
|
Dr. Denise Croix
"A Look into the Current PD-L1 Landscape and to the Journey Ahead" |
The cancer immunity cycle is central to immune surveillance and defense, and manages the delicate balance between the recognition of non-self and the prevention of autoimmunity. Cancer cells have, however, developed mechanisms to evade immune detection and destruction (1). The activation of T cells is regulated though a large number of activating and inhibitory checkpoint signals that both enhance and suppress these functions and enable T cell responses to be adaptive. This understanding of the critical role of the immune system in cancer has resulted in significant clinical breakthroughs in recent years. The first checkpoint pathway to be successfully targeted by monoclonal antibodies was the cytotoxic T-lymphocyte associated protein 4, or CTLA-4. The next was the PD-1, or programmed death 1 receptor pathway. The PD-1 gene was discovered in 1992 when it was found to be upregulated during cell death in lymphocytes. It’s ligand, PD-L1, was discovered in 1999. This is a type 1 transmembrane protein that can be expressed on many cell types, including antigen presenting cells, lymphoid cells and tumor cells (2).
Targeting the PD-1/PD-L1 pathway with checkpoint inhibitors has demonstrated durable responses across a range of tumor types. The FDA has approved PD-1/PD-L1 inhibitors for the treatment of 10 cancer types and some tumor agnostic therapies. Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab and Avelumab all have FDA approved PD-L1 companion or complementary diagnostic assays associated with them (3). This landscape is ever changing and can be quite complex as each assay as each has its own FDA approval which consist of clone, instrument, detection system and even interpretation guide. Requirements to use and score the diagnostic assay can vary not only between therapies but also between disease states. We will provide a broad understanding of the landscape today and how it may look in a few years with the numerous clinical trials that are still ongoing as of today. Objectives of this presentation will be to understand; 1. the PDL-1 cancer immunity cycle, 2. the difference between complementary and companion FDA approvals, and 3. A high level overview of different scoring algorithms in urothelial carcinoma (22C3 and SP263), NSCLC ( SP142), and cervical cancer (CPS score 22c3). |
SATURDAY, JUNE 20TH - 9am - 10am EST
|
Michelle Schwab
"Inspirational Leadership" |
Whether you are in leadership or simply aspire to be a leader someday, having a solid foundation is the key to being successful. People-management is a critical part of a successful organization, and this course will further your skills and knowledge in laboratory management and leadership. We will first identify the key leadership skills for creating a happy and effective lab culture. You will then learn to assess your own leadership skills and how they play a crucial role in creating the right work environment for yourself and your team. Finally, we will dive into how to figure out what skills you already possess and those you want to hone, along with how to put a team together in a way that will simply make life better.
|
